Prolong - About Us

Prolong is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated products that treat prevalent conditions and address unmet medical needs and orphan diseases. Headquartered in South Plainfield, New Jersey, Prolong is committed to developing novel biologics to treat several diseases and their debilitating comorbidities associated with reduced quality of life, increased medical cost, and significant mortality. The Company is currently developing a portfolio of products in stroke, hematology, and oncology.

The Origin

Originally established in 2005 as a research lab, Prolong has emerged as a mature, privately held biotech company with an active clinical development program and has a large-scale cGMP manufacturing facility on-line.

The founders of Prolong were among the pioneers in PEGylation achieving the first regulatory approval of a PEGylated protein therapeutic (Adagen, Enzon, 1990).

The chemistry of “PEG” has exploded since this product launch such that now there exists a near infinite palette of chemical linkers and molecular sizes for PEGylation considerations. This PEGylation technology is responsible for the development of many drugs aiming to improve the quality of life for sufferers of hepatitis, kidney disease, and several other life-threatening diseases.

meet the team

Transformative Medicine through Innovative Design with Proven Technology

PEGfinity™ was created at Prolong to leverage the prior PEGylation experience, and in combination with in-silico analysis methods, to achieve comprehensive PEGylation coverage of the entire protein in rapid order. Drug library generation and lead candidate selection follows an iterative structure/function analytical process that is specifically defined for each protein and clinical indication.

learn more about sanguinate

Learn how you can be part of the journey

Join us in revolutionizing treatments for severe
and life-threatening conditions

call us

email our team

Meet Prolong Pharmaceuticals

Originally established in 2005 as a research lab, Prolong has emerged as a mature, privately held biotech company with an active clinical development program and has a large-scale cGMP manufacturing facility on-line.

Transformative Medicine through Innovative Design with Proven Technology

Learn how you can be part of the journey